Tissue Regenix secures $20m in loan facilities

Writer, Stock Market Wire
Tuesday, June 4, 2019 - 07:31

Regenerative medical devices company Tissue Regenix Group said some of its subsidiaries had agreed with MidCap Financial Trust to access a revolving credit facility and a term loan credit facility of up to $20m.

Funding of $10.5m was initially available to the company, of which it planned to draw down an initial $7.5m immediately.

The initial net proceeds would be used to invest in additional capital expenditure to sustain future business growth.

They would also be used to generate further clinical and economic data to support brand differentiation within dCELL and BioRinse, and for general corporate and working capital purposes.

Interest on the outstanding balance of the term loan would be payable at an annual rate of one month US Libor plus 6.75% subject to a one-month US Libor floor of 2.25%.


Related content

Tissue Regenix expects to breach revenue loan covenant; in talks with lender

Regenerative medical devices company Tissue Regenix said it was in talks with loan provider MidCap Financial Trust after assessing that it would likely breach on...

Mon, 11/11/2019 - 08:21


Tissue Regenix posts first-half loss; sees better second half

Regenerative medical devices company Tissue Regenix posted a first-half loss but said it expected to post a better performance in the second half owing to...

Tue, 10/09/2019 - 15:02


Tissue Regenix appoints Mike Barker as permanent CFO

Regenerative medical devices company Tissue Regenix said it had appointed Mike Barker as its chief financial officer.

Barker had been assisting the company as interim...

Wed, 28/08/2019 - 07:49


Tissue Regenix signs 10-year lease on facility in US to ramp up processing capacity

Medical devices group Tissue Regenix signed a 10-year lease agreement on a facility to expand processing capacity at its manufacturing base in San Antonio, Texas....

Thu, 15/08/2019 - 08:46


CEO Steve Couldwell resigns from Tissue Regenix due to illness

Regenerative medical devices company Tissue Regenix Group said that CEO Steve Couldwell had resigned his position 'with immediate effect' due to a recurrence of illness....

Thu, 01/08/2019 - 09:45